We present the molecular landscape of pediatric acute myeloid leukemia (AML), characterizing nearly 30 1,000 participants in Children's Oncology Group (COG) AML trials. The COG/NCI TARGET AML initiative 31 assessed cases by whole-genome, targeted DNA, mRNA, miRNA sequencing and CpG methylation 32 profiling. Validated DNA variants revealed diverse, infrequent mutations with fewer than 40 genes 33 mutated in >2% of cases. In contrast, somatic structural variants, including novel gene fusions and 34 focal MBNL1, ZEB2, and ELF1 deletions, were disproportionately prevalent in young as compared to 35 adult patients. Conversely, DNMT3A and TP53 mutations, common in adults, are conspicuously absent 36 from virtually all pediatric cases. Novel GATA2, FLT3, and CBL mutations, recurrent MYC-ITD, NRAS, 37 KRAS, and WT1 mutations are frequent in pediatric AML. Deletions, mutations, and promoter DNA 38 hypermethylation convergently impact Wnt signaling, Polycomb repression, innate immune cell 39 interactions, and a cluster of zinc finger genes associated with KMT2A rearrangements. These results 40 highlight the need for, and facilitate the development of age-tailored targeted therapies for the 41 treatment of pediatric AML. 42 43
The WGS discovery cohort of diagnostic and remission (germline comparison) specimens were selected 68 from patients treated on recent COG studies who achieved an initial remission to induction 69 chemotherapy. These trials randomized type or timing of induction therapy (CCG-2961) 8 and the 70 addition of gemtuzumab ozogamicin in a single arm pilot (AAML03P1) 9 or randomized fashion 71 (AAML0531) 10 . Specimens for TCS validation were obtained from 800 patients, including 182 from the 72 WGS discovery cohort (153 with matched remission samples). A complete listing of cases and their 73 characterization is available in the TARGET sample matrix 74
(https://ocg.cancer.gov/programs/target/data-matrix). The age at presentation of TARGET AML 75 participants ranged from 8 days to 29 years (median 10 years, Fig. 1a ). Infants (<3 years old), children 76
(age 3-14) and adolescents/young adults (AYA; age 15-39) differ broadly by cytogenetic and clinical risk-77 group classifications ( Fig. 1a , multivariate Chi-squared p<10 -22 ), consistent with observed differences in 78 clinically-evaluated structural abnormalities and mutations (summarized in Fig. 1b) . Notably, among 79 these clinically detected abnormalities, only 5 mutations and 5 structural aberrations occur in more than 80 5% of patients (mutations in FLT3, NPM1, WT1, CEBPA, and KIT; fusions involving RUNX1, CBFB and 81 KMT2A; trisomy 8 and loss of the Y chromosome.) 82
We validated each class of somatic DNA sequence alteration discovered by WGS through secondary 83 assays (Figs. 1c and S1). Single nucleotide variants (SNVs) and short insertions and deletions (indels) 84
were confirmed by TCS of the coding sequences of the genes identified as recurrently altered in the 85 WGS studies. WGS-detected copy number alterations were confirmed by GISTIC2.0 scores from SNP 86 arrays; WGS-detected structural changes (such as translocations and inversions) were confirmed by 87
RNA-seq and clinical leukemia karyotyping data. Across variant types, we find >70% concordance 88 between at least two assays. These variants are referred to as verified variants hereon. An overview of 89 the multiplatform-verified somatic DNA variants in 684 patients is presented in Fig. 2a . Roughly a 90 quarter of patients possess normal karyotype, yet nearly all revealed at least one recurrent verified 91 somatic DNA alteration, and at least 12 common cancer-associated cellular processes are recurrently 92 impacted ( Fig. S2, Tables S2a, b) . 93 We carried out analyses of microRNA, mRNA, and/or DNA methylation in 412 subjects. A summary of 94 the assays performed and case-assay overlap is presented in Fig. S3 . We compared our verified variants 95 to those of 177 adult AML cases from The Cancer Genome Atlas (TCGA) project 3 , stratified by the age 96 groupings outlined in Fig. 1a . The TARGET and TCGA discovery cohorts both contained numerous AYA 97 patients (Table S3 ). Importantly, our conclusions regarding the molecular characteristics of this age 98 group are identical when analyzing either or both cohorts (Fig. S4) . 99
Somatic gene mutations in pediatric AML 100
Like adult AML, pediatric AML has one of the lowest rates of mutation among molecularly well-101 characterized cancers (Fig. S5) , with < 1 somatic, protein-coding change per megabase in most cases. 102
However, the landscape of somatic variants in pediatric AML is markedly different from that reported in 103 adults 3, 4 (Figs. 2b, S6-S7 , Table S4 ). RAS, KIT, and FLT3 alterations, including novel, pediatric-specific 104
FLT3 mutations (FLT3.N), are more common in children. Mutational burden increases with age, yet older 105 patients have relatively fewer recurrent cytogenetic alterations. Indeed, the number of coding SNVs, 106
within and across cohorts, is best predicted by age ( Fig. 2c, p<10 -15 ) and by cytogenetic subgroup. In 107 contradistinction to the higher prevalence of small sequence variants in older patients, recurrent 108 structural alterations, fusions, and focal copy number aberrations are more common in younger patients 109 (Figs. 2d-e, p<10 -3 , see below). Patients with CBFA2T3-GLIS2, KMT2A, or NUP98 fusions tend to have 110 fewer mutations (p<10 -9 ), with subgroups demonstrating inferior clinical outcome (Fig. S8) . Patients with 111 core binding factor rearrangements tend to have more mutations than expected for their age (p<10 -15 ), 112 yet more favorable outcomes. The mutational spectrum of coding SNVs (Fig. S5) accumulates C→T 113 transitions with age (p<10 -3 ), with additional C→A transversions in t(8;21) (p<10 -2 ) and aberrant 114 karyotype (p<10 -2 ) patients. 115
After adjustment for cytogenetics and multiple comparisons, NRAS (p<10 -3 ) and WT1 (p<10 -3 ) are 116 mutated significantly more often in younger patients, while DNMT3A (p<10 -23 ), IDH1/2 (p<10 -4 ), RUNX1 117 (p<10 -4 ), TP53 (p<10 -4 ), and NPM1 (p<0.03) are mutated significantly more frequently in older patients. 118 KRAS, CBL, GATA2, SETD2, and PTPN11 mutations appear to be more common in younger patients 119 (0.05<p<0.1, adjusted, Figs. S7 and S9). We identified a prominent hotspot of MYC alterations 11 and 120 previously unreported internal tandem duplications appearing exclusively in children (Fig. S7) . These 121 observations are replicated in an independent ECOG cohort ( Fig. S10a) of 384 adult AML patients 5 . Since 122 gene fusions have characteristic cooperating mutations 12 , we devised a weighted resampling scheme to 123 compare mutation frequencies in 584 TARGET and 131 TCGA AML cases while controlling for karyotypic 124 associations. The results ( Fig. S10b) confirm the generality of the pediatric-adult differences identified 125
above. 126
For genes such as CBL, GATA2, WT1, MYC and FLT3, both the frequency and the sites of mutation often 127 differ between children and adults ( Figs. 3a and S7) , with multiple -frequently recurrent-alterations 128 distinct from those identified in adult AML. RAS-related mutations (mutant KRAS, NRAS, PTPN11, or NF1) 129 are common, particularly with KMT2A fusions (Fig. S11, Tables S4-S6 ). In addition to being more 130 common and varied, WT1 mutations appear more likely to be of clonal origin in younger patients ( Fig.  131 3b) despite the majority of pediatric patients presenting with multiple detectable sub-clones ( Fig. S12) . 132 These differences are clinically significant: we have previously shown that novel FLT3 mutations are 133 functional, and yield poor responses to standard therapy 13 . The established adverse impact of FLT3-ITDs 134 on survival is significantly modulated by co-occurring variants, including WT1 and NPM1 mutations and 135
NUP98 translocations. As shown in Figs. 3c and S13-S14, three independent, large-scale studies 136 demonstrate that FLT3-ITD accompanied by NPM1 mutations is associated with relatively favorable 137 outcomes in pediatric patients, while FLT3-ITD with WT1 mutations and/or NUP98-NSD1 fusions yields 138 poorer outcomes than FLT3-ITD alone. 139
We found no coding mutations in DNMT3A in pediatric AML, despite its high frequency in adults. 140
Spontaneous deamination of 5-methylcytosine is strongly associated with aging, and DNMT3A contains 141 a CpG dinucleotide yielding hotspot R882 mutations by C-to-T deamination 14 . DNMT3A also directly 142 interacts with TP53 15 , itself impacted far more frequently in adults. Mutations of DNMT3A or TP53 drive 143 clonal hematopoiesis in many apparently healthy adults 16 but are rare in children, as are the IDH1 and 144
IDH2 mutations with which they often co-occur. 145
The spectrum of somatic structural DNA changes in pediatric AML 146 Many pediatric AML cases harbor chromosomal copy number changes distinct from those reported in 147 adults ( Fig. 4a) Fig. S16 ). Among 157 other novel recurrent copy losses, we note five heterozygous deletions of a region containing the IL9R 158 gene (Table S5 ) co-occurring with KIT mutations and t(8;21). 159
Consistent with our previous findings regarding NUP98-NSD1 fusions 20 , an expansive catalog of gene 160 fusions, many observed primarily or exclusively in pediatric cases, underscores the disproportionate 161 impact of structural variants in younger patients (Figs. 4b and S17-S18). But patterns of exclusion and 162 cooperation are not limited to patients with recurrent structural alteration: mutant GATA2 is frequently 163 seen in children with normal karyotype (NK) AML, and both GATA2 (p<10 -9 ) and CSF3R (p<10 -6 , Fig. S19 ) 164 mutations co-occur with mutations of CEBPA 21 . GATA2 and CEBPA are key regulators of 165 hematopoiesis 22,23 , both interacting with RUNX1 in normal hematopoiesis and leukemogenesis 24 . As with 166 FLT3/NUP98-NSD1/WT1 interactions, these findings show prognostic interactions in pediatric AML 167 outcome ( Fig. S19b) . RUNX1 mutations and RUNX1-RUNX1T1 gene fusions are significantly exclusive of 168 GATA2 and CEBPA mutations (p=0.006, Fig. S20 , Table S7 ). All four are significantly exclusive of KMT2A 169 rearrangements (p<10 -15 ), CBFB-MYH11 gene fusions (p<10 -11 ), and ETV6 aberrations (p=0.01). 170
DNA methylation subtypes in pediatric AML 171
As summarized in Fig. 4c we previously reported to predict poor survival 29 . 201 Differential expression analyses using Wilcoxon tests revealed miRNAs that are differentially expressed 202 between pediatric and adult AML ( Fig. 6b) . Of note, miR-330 was the most over-expressed in pediatric 203 samples, and has previously been shown to have oncogenic potential in AML 30 . 204
Several age-associated miRNAs harbor binding sites within, and have expression levels anti-correlated 205
with, putative target genes that may be involved in RNA and protein processing suggesting that miRNAs 206 could contribute to leukemogenesis through the dysregulation of transcripts and proteins 31 . Of note, 207
let-7b, which is a potential regulator of protein synthesis via EIF2S3 (Fig. 6c) , is typically less abundantly 208 expressed in pediatric AML ( Fig. 6d) . However, high let-7b expression in pediatric AML is associated with 209 shorter time to relapse (log-rank p<0.05, Fig. 6e ). 210 211 Discussion 212 Using a large cohort of patients, this study establishes the prevalence of, and coincident relationships 213 among, recurrent somatic genetic and epigenetic abnormalities in pediatric AML. We observe several 214 features in common between pediatric and adult AML: a low overall mutation rate in comparison to 215 other cancers, a long tail of infrequently affected genes, and overlap among recurrently impacted genes. 216
However, pediatric AML exhibits distinctive and critically important characteristics. We and others have 217 previously reported on the presence and clinical impact of novel fusion genes in pediatric AML 20,32 . As 218 this study illustrates, the impact of fusion transcripts in AML is both broad and age-dependent. 219
Recognition and comprehensive testing for these alterations are key first steps in the development of 220 new and potentially novel modes of targeted therapy 33 . 221
Recurrent focal deletions represent a unique aspect of pediatric AML. Regional (e.g. chromosomal arm-222 and band-level) copy loss differs substantially by age, but surprisingly, focal areas of copy loss are also 223 more common in children, specifically impacting ZEB2, MBNL1, and ELF1. MBNL1 is upregulated by the 224 KMT2A-AF9 fusion protein 34 , and genes involved in post-transcriptional processing (SETD2, U2AF1, 225 DICER1) harbor the sole recurrent mutation in several KMT2A-rearranged cases, suggesting a functional 226 role for altered splicing in pediatric leukemogenesis. Alterations in ZEB2 have been identified as 227 cooperating events in murine CALM-AF10 leukemia models 35 while ZEB2 knockout mice develop 228 myelofibrosis 36 , suggesting a fundamental role for this gene in the pathogenesis of AML. 229
Many of the genes characteristically mutated in AML are altered at widely variable frequencies across 230 age groups; several (including FLT3 and WT1) are impacted by pediatric specific variants and hotspots. 231
Clinical tests for a handful of genomic alterations are widely used to risk-stratify patients and determine 232 treatment regimens. However, the current practice of considering the effect of each somatic alteration 233 in isolation is inadequate. As we illustrate for FLT3-ITD, interactions among sequence variants can have 234 dramatic clinical consequences. Moreover, some interactions appear to be age-specific. In pediatric 235 AML, FLT3-ITD and NPM1 mutations co-occur in the absence of DNMT3A mutations in a group of 236 patients with superior outcomes (Figs. 3c, S13 and S14), in contrast to inferior outcomes reported in 237 adults where FLT3-ITD and NPM1 mutations frequently co-occur with mutations in DNMT3A 4 . In the 238 TCGA adult AML cohort, over half the subjects with somatic FLT3 and NPM1 mutations also possessed 239 somatic DNMT3A mutations 3 . Subsequent studies established the generality of this result 4 , and revealed 240 that DNMT3A mutations are early clonal events 37 , which often co-operate with later NPM1 and FLT3 241 mutations to promote chemoresistance, mutagenesis, 38 and inferior outcomes 39 . Similarly, the co-242 occurrence of FLT3-ITD with WT1 mutations or NUP98-NSD1 fusions accompanies frequent induction 243 failure and dismal outcomes in children with AML (multivariate p<10 -4 , Figs. 3c, S13 and S14). 244
In TARGET, TCGA, and ECOG AML cases, WT1 mutations were mutually exclusive with those of ASXL1 245
and EZH2 (p < 10 -3 ). WT1 recruits EZH2 to specific targets 40 , and WT1 mutations have been linked to 246 promoter DNA hypermethylation of EZH2 target genes 41 . Mutant ASXL1 abolishes EZH2-mediated 247 silencing of HOX genes 42 . EZH2 resides on a recurrently deleted region of chromosome 7, and decreased 248
EZH2 activity is associated with treatment resistant AML 43 . In pediatric AML, mutant WT1 and EZH2 249 appear to be of exclusively clonal or near-clonal origin, with nearly a quarter of TARGET cases harboring 250 mutations affecting one or the other. Aberrant WT1, EZH2, or ASXL1 predicted induction failure in 251
TARGET AML cases (multivariate p<0.05, adjusted for interactions with FLT3 alterations, NUP98-NSD1, 252
and KMT2A fusions) and were largely mutually exclusive with KMT2A rearrangements (p < 10 -5 ). Many of 253 these patients present without apparent chromosomal abnormalities at diagnosis, yet less than 20% 254 achieve long-term remission with standard treatment, highlighting the importance of molecular 255 stratification to achieve better outcomes. It is possible that early events such as WT1 mutations and 256
NUP98-NSD1 fusions in children may play a similar role to that observed for DNMT3A mutations 14 in 257 adults, with significant implications for risk stratification in AML across age groups. 258
Our data also demonstrate that DNA-methylation and miRNA expression profiles both accompany and 259 complement DNA alterations, and can stratify pediatric AML patients in terms of both overall and 260 progression-free survival. These findings suggest a need to update pediatric AML clinical risk categories 261 beyond current classifications, with important implications for clinical practice. 262
Despite incremental improvements with increasingly intensified regimens, modern outcomes in 263 pediatric AML have plateaued, with only ~60% of patients achieving long term survival. As many as 10% 264 of children will die from direct complications of treatment. Survivors suffer unacceptably high rates of 265 long-term morbidities resulting from anthracycline exposure or sequelae of hematopoietic stem cell 266 transplantation. As illustrated herein, pediatric AML is a collection of molecularly diverse diseases with 267 similar phenotypes. No single treatment strategy is likely to be effective for all pediatric AML subtypes, 268
which may explain repeated failures of randomized clinical trials to improve outcomes in recent years. In 269 keeping with the shift towards comprehensive, molecularly based classification schemas in AML 4 , the 270 time has come to develop targeted therapies that address specific vulnerabilities of pediatric subtypes. 271
The TARGET AML dataset will serve as a foundation for development of pediatric-specific classification 272 schemas and the development of personalized treatment strategies. 273
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to be greatest in infants compared to all other ages (Chi-squared p < 10 -22 ). KMT2A fusions are most 331 common in infants (Chi-squared p < 10 -20 ), while core binding factor fusions tend to affect older children 332
(Chi-squared p < 10 -7 ). 333 . S13 ), while co-occurrence of NPM1 346 mutations with FLT3-ITD associates with improved survival. These findings are confirmed by two 347 separate studies from which TARGET cases were selected (AAML0531 and CCG-2961) as well as an 348
Figure 3. Biological and prognostic interactions between alterations of WT1, NPM1, FLT3-ITD and
independent cohort of patients treated on European cooperative group trials (DCOG, see online 349 methods). 350 . S24 ). The patient-specific score matrix and display of all 31 signatures are provided 381
in Table S10 and and molecular features (e.g., KIT, RAS, NPM, WT1, CEBPA, IDH1 mutations, and FLT3/ITD allelic ratios) 502
were clinically available prior to genomic analyses and are included in the clinical data file available at 503 the TARGET data matrix. 177 cases from the adult de novo AML TCGA dataset 3 were selected for 504 analysis after exclusion of those with FAB M3 morphology (n=20) or BCR-ABL1 gene fusion (n=3) since 505 these subtypes are not represented in the COG/TARGET-AML cohort. The age distributions for the 506 TARGET WGS discovery group and the TCGA cohort are outlined in Table S3 . 507 DNA and RNA was extracted from ficoll-enriched, viably cryopreserved samples from the COG 508 biorepository using the AllPrep Extraction Kit (Qiagen). Nucleic acids were quantified by NanoDrop 509 (Thermo Scientific). RNA samples were tested for quality and integrity using the Agilent 2100 510
Bioanalyzer (Agilent Technologies Project (PCGP), and CGI WGS from the TARGET project. For step 2, a mutation is considered of low-522 confidence if it does NOT meet one of the following criteria: a) mutant allele has ≥3 more read count in 523 tumor than in the normal sample; b) the mutant read count in tumor is significantly higher than that in 524 the matched normal (P<0.01 by Fisher exact test); and c) mutant allele fraction in normal is below 0.05. 525
For step 3, we ran BLAT search using a template sequence that includes the mutant allele and its 20-bp 526 flanking region to determining the uniqueness of mapping of the mutation. To avoid over-filtering, we 527 implemented a rescue pipeline which retains all "gold" variants that match known somatic mutation 528 hotspots based on our variant classification program Medal Ceremony 45 . 529
In addition to small variant calls (SNV, indel), the CGI cancer analysis pipeline delivered flat files of 530 potential novel DNA junctions and segmented copy number ratios derived from normalized read counts 531 from paired tumor/normal specimens. predictor) and cytogenetic subgroup (as a categorical predictor) were uniformly and highly significant, as 620 reported in the text, while the per-cytogenetic-group random effects accounted for a small (< 0.003%) 621 fraction of the variance observed. The model converged in 208 steps; 10,000 MCMC iterations were 622 employed to estimate the mixed effects component of the model, fitted per-cytogenetic-group 623
assuming a random slopes model. 624
Generalized Dirichlet-multinomial regression for mutational spectra. To accommodate the possibility 625 of either negative or positive correlation between the counts of each type of mutation (C→T, C→A, 626 C→G, T→C, T→A, T→G) in each subject, we employed a generalized Dirichlet-multinomial model 627
(mglm 53 , R package version 0.0.7, https://CRAN.R-project.org/package=MGLM) with age and 628 cytogenetic group as predictors, mutational spectrum (a matrix of counts for each type of mutation) as 629 response. At convergence, the significant predictors of mutational spectrum differences were age (most 630 significant), t(8;21) status, and aberrant karyotype (mutually exclusive with t(8;21) and other common 631 recurrent chromosomal abnormalities). C→T transitions are known to increase with age, particularly for 632 methylated cytosines; however, an inflation of C→A transversions was particularly apparent in t(8;21) 633 and aberrant karyotype cases. (Both t(8;21) and inv(16) affect core binding factor subunits, and both are 634 associated with higher mutational burdens at a given age, but only t(8;21) cases show additional C→A 635 transversions beyond those expected from counts). 636
Weighted resampling scheme to compare TARGET and TCGA mutation frequencies. Common 637 chromosomal aberrations often co-occur with specific types of additional DNA sequence abnormalities. 638
To account for this observation when determining differences in mutation frequencies between TARGET 639 AML and TCGA AML, we first divided each cohort into the following categories: KMT2A fusions, t(8;21), 640 inv(16), del(7), +8, +21, -Y, and normal karyotype (NK). A total of 131 unique TCGA and 548 TARGET 641 samples fell into one of the above categories. We then sampled equal numbers of specimens from each 642 category and calculated the fraction of samples with mutations in a given gene. To account for sampling 643 variations, we repeated our sampling procedure 5000 times and calculated the mean and standard 644 deviation of the fraction of samples with mutations in each gene of interest. 645
Variant pairwise mutual exclusion and co-occurrence. Pairwise mutually exclusive sequence alterations 646 ( Fig  S20a) were identified using CoMEt 54 with the "exhaustive" option 647
(http://compbio.cs.brown.edu/projects/comet/). Pairwise co-occurrence p-values ( Fig S20b) were 648 calculated directly using a hypergeometric distribution (equivalent to Fisher's exact test). Statistically 649 significant exclusion/co-occurrence patterns were visualized using Cytoscape 55 (http://cytoscape.org/), 650
with edge thickness representing -log10(p-value). 651
Orthogonal evaluation of mutual exclusion and co-occurrence via penalized Ising model. A slightly 652 different approach to reconstructing a binary-valued undirected graph (a discrete Markov random field) 653 employs penalized logistic regression of all candidate nodes upon each possible target and selects the 654 most probable graph structure based on extensions of the Bayes information criterion (EBIC). This 655 approach is implemented by Epskamp (https://cran.r-project.org/package=IsingFit) 56 and employs a 656 hyperparameter (γ) for the penalty weight which eventually determines the density of the estimated 657 network. Adjustment for multiple comparisons was applied to the marginal significance of each gene-658 gene Fisher exact test; this value is not unbiased due to post-selection inference and is only intended as 659 a guide. The resulting network of correlated and anticorrelated binary indicators (gene-and 660 chromosomal-level aberrant/wildtype, pediatric/adult) recovers known and CoMEt-detected 661
relationships, but also identifies several novel and marginally significant (by Fisher's exact test, see 662 above) relationships, as summarized in Supplementary Table 6 . 663 Fusion mRNA Transcript Detection. Transcriptomic data were de novo assembled using ABySS (v1.3.2) 748
and trans-ABySS (v1.4.6) 62 . For RNA-seq assembly alternate k-mers from k50-k96 were performed using 749 positive strand and ambiguous stand reads as well as negative strand and ambiguous strand reads. The 750 positive and negative strand assemblies were extended where possible, merged and then concatenated 751 together to produce a meta-assembly contig dataset. Large scale rearrangements and gene fusions from 752
RNA-seq libraries were identified from contigs that had high confidence GMAP (v2012-12-20) alignments 753 to two distinct genomic regions. Evidence for the alignments were provided from aligning reads back to 754 the contigs and from aligning reads to genomic coordinates. Events were then filtered on read 755
thresholds. Insertions and deletions were identified by gapped alignment of contigs to the human 756 reference using GMAP. The events were then screened against dbSNP and other variation databases to 757 identify putative novel events. 758 miRNA Sequencing. Small RNAs, containing microRNA (miRNA), in the flow-through material following 759 mRNA purification on a MultiMACS separator (Miltenyi Biotec) are recovered by ethanol precipitation. 760
miRNA-seq libraries are constructed using a 96-well plate-based protocol developed at the BC Cancer 761
Agency, Genome Sciences Centre. Briefly, an adenylated single-stranded DNA 3' adapter is selectively 762 ligated to miRNAs using a truncated T4 RNA ligase2 (New England Biolabs). An RNA 5' adapter is then 763 added, using a T4 RNA ligase (Ambion) and ATP. Next, first strand cDNA is synthesized using Superscript 764 II Reverse Transcriptase (Invitrogen), and serves as the template for PCR. Index sequences (6 765 nucleotides) are introduced at this PCR step to enable multiplexed pooling of miRNA libraries. PCR 766 products are pooled, then size-selected on an in-house developed 96-channel robot to enrich the miRNA 767 containing fraction and remove adapter contaminants. Each size-selected indexed pool is ethanol 768 precipitated and quality checked on an Agilent Bioanalyzer DNA 1000 chip and quantified using a Qubit 769 fluorometer (Invitrogen, cat. Q32854). Each pool is then diluted to a target concentration for cluster 770 generation and loaded into a single lane of a HiSeq 2000 flow cell for sequencing with a 31-bp main read 771 (for the insert) and a 7-bp read for the index. 772
Sequence data are separated into individual samples based on the index read sequences, and the reads 773 undergo an initial QC assessment. Adapter sequence is then trimmed off, and the trimmed reads for 774 each sample are aligned to the NCBI GRCh37-lite reference genome. 775
Routine QC assesses a subset of raw sequences from each pooled lane for the abundance of reads from 776 each indexed sample in the pool, the proportion of reads that possibly originate from adapter dimers 777 (i.e. a 5' adapter joined to a 3' adapter with no intervening biological sequence) and for the proportion 778 of reads that map to human miRNAs. Sequencing error is estimated by a method originally developed 779 for SAGE. 780
Libraries that pass this QC stage are preprocessed for alignment. While the size-selected miRNAs vary 781 somewhat in length, typically they are ~21 bp long, and so are shorter than the 31-bp read length. Given 782 this, each read sequence extends some distance into the 3' sequencing adapter. Because this non-783 biological sequence can interfere with aligning the read to the reference genome, 3' adapter sequence is 784 identified and removed (trimmed) from a read. The adapter-trimming algorithm identifies as long an 785 adapter sequence as possible, allowing a number of mismatches that depends on the adapter length 786 found. A typical sequencing run yields several million reads; using only the first (5') 15 bases of the 3' 787 adapter in trimming makes processing efficient, while minimizing the chance that a miRNA read will 788 match the adapter sequence. 789
After each read has been processed, a summary report is generated containing the number of reads at 790 each read length. Any trimmed read that is shorter than 15bp is discarded; remaining reads are 791 submitted for alignment to the reference genome. BWA (Li and Durbin, 2009 ) alignment(s) for each read 792 are checked with a series of three filters. A read with more than 3 alignments is discarded as too 793
ambiguous. Only perfect alignments with no mismatches are used. Reads that fail the Illumina 794 basecalling chastity filter are retained, while reads that have soft-clipped CIGAR strings are discarded. 795
For reads retained after filtering, each coordinate for each read alignment is annotated using a 796 reference database, and requiring a minimum 3-bp overlap between the alignment and an annotation. If 797 a read has more than one alignment location, and the annotations for these are different, we use a 798 priority list to assign a single annotation to the read, as long as only one alignment is to a miRNA. When 799 there are multiple alignments to different miRNAs, the read is flagged as cross-mapped (de Hoon et al., 800
2010), and all of its miRNA annotations are preserved, while all of its non-miRNA annotations are 801 discarded. This ensures that all annotation information about ambiguously mapped miRNAs is retained, 802
and allows annotation ambiguity to be addressed in downstream analyses. Note that we consider 803 miRNAs to be cross-mapped only if they map to different miRNAs, not to functionally identical miRNAs 804 that are expressed from different locations in the genome. Such cases are indicated by miRNA miRBase 805 names, which can have up to 4 separate sections separated by "-", e.g. hsa-mir-26a-1. A difference in 806 the final (e.g. '-1') section denotes functionally equivalent miRNAs expressed from different regions of 807 the genome, and we consider only the first 3 sections (e.g. 'hsa-mir-26a') when comparing names. As 808 long as a read maps to multiple miRNAs for which the first 3 sections of the name are identical (e.g. hsa-809 mir-26a-1 and hsa-mir-26a-2), it is treated as if it maps to only one miRNA, and is not flagged as cross-810 mapped. 811
The minimum depth of sequencing required to detect the miRNAs that are expressed in one sample is 812 1,000,000 reads per library mapped to miRBase (v21) annotations. Finally, for each sample, the reads 813 that correspond to particular miRNAs are summed and normalized to a million miRNA-aligned reads to 814 generate the quantification files. TARGET and TCGA miRNA quantifications were normalized with pSVA, 815
preserving known subtype-specific miRNA expression patterns, prior to comparison 63 
Transcriptional silencing evaluation and tabulation 849
Transcription is influenced by a large number of features, among which is methylation of genomic CpG 850 dinucleotides, which often leads to methyl-binding domain proteins excluding transcriptional activators 851 when it occurs near a transcription start site. Not all gene promoters are influenced by differences in 852 DNA methylation, and not all promoters which are thusly influenced are relevant in a given cell type. 853
Thus we sought to identify bundles of transcripts (genes) whose expression appears to be influenced by 854
promoter CpG methylation and whose expression potential is perturbed in a subset of AML cases. 855
To establish a uniform criteria for "calling" such events, we evaluated over 50,000 loci from the Illumina 856
HumanMethylation450 ("450k") microarray near the transcription start sites of over 20,000 transcripts. 857
Where any variance in transcript abundance was explained by variation in DNA methylation levels at a 858 locus, we retained the locus and gene symbol for further evaluation. With this set of several thousand 859 potential marker pairs, we iteratively sought "silencing" cutoff points, such that the maximum 860 expression of a gene in any sample with methylation above the cutoff level was less than or equal to the 861 median expression of samples below the cutoff. The relative levels of DNA methylation and expression 862 appeared to differ systematically between TCGA AML and TARGET AML patients. Therefore we retained 863 the most conservative (highest) cut-point from among the two cohorts. A large number of TARGET AML 864 patients were previously assayed on the promoter-centric Illumina HumanMethylation27 ("27k") 865 microarray; to maximize the sample size for silencing calls, we performed the same conservative 866 procedure as described above with 27k loci. Whenever a locus could be found with a suitable cut-point 867 on both 27k and 450k arrays, we used the two loci to cross-validate transcriptional silencing behavior 868 between the two (largely disjoint) sets of samples (TCGA AML patients were assayed on both 27k and 869 450k arrays, so we used the appropriate complementary assay to cross-validate each cutoff in TCGA). 870
The resulting set of "tag CpGs" (loci with satisfactory cutoff values for a given gene) on each platform, 871
along with the results of applying these cutoffs to dichotomize patient samples into "silenced" or not, 872 are provided in Table S9 . Selected loci and genes affected across multiple patients are plotted in Fig. 5a , 873 annotated within each major cytogenetic group by the fraction of patients silenced. as 13, again based on reconstruction error as above), we subtracted "normal" hematopoietic cell signals 895 and simultaneously estimated the purity (cellularity) of each tumor sample, which allowed us to amplify 896 disease-specific signals, correcting in silico for estimated purity on a logit scale, and finally transforming 897 back to the original proportional 0-1 scale for presentation in Fig. 5b . The 31-row by 284-column patient 898 score matrix H, are provided in Table S10 ; selected signatures of particular interest are plotted in Fig.  899 5b. Ward's method was employed to cluster columns (patients) in the figure panel by Manhattan 900
distance. 901
Survival analysis. 902
We tested an additional cohort of pediatric AML patients for outcome measures associated with 903 alterations of FLT3-ITD, NPM1 and WT1 mutations and NUP98-NSD1 translocations (Fig. 3C, lower The Kaplan-Meier method was used to estimate overall survival (OS) and event free survival (EFS). OS is 919 defined as the time from study entry until death. EFS is defined as the time from study entry until death, 920 induction failure, or relapse. Patients lost to follow-up were censored at their date of last known 921 contact. Comparisons of OS and EFS were made using the log-rank test. 922 TARGET and TCGA subjects were combined in Cox proportional hazards fits for association of DNA 923 methylation signatures with survival outcome, and model parameters for well-established risk factors 924 (TP53 mutation, white blood cell count at diagnosis) were also estimated. Due to the nonlinear 925 association of age with survival in pediatric AML patients, and the difficulty of properly evaluating this 926 relationship, we instead stratified the Cox proportional hazards fits by cohort. 927
For miRNA associated survival analyses, the expression (RPM) cut point between high and low 928 expression groups for each miRNA was defined using the X-tile method 80 , where all separation points 929 between patients were considered and the selected cut point was the one that provided the optimal 930 (lowest) EFS log rank p-value. 931
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For additional information on experimental design, methods and reagents, please see the associated "Life 933
Sciences Reporting Summary Report" file. 934 NRAS  KIT  KRAS  WT1  FLT3.N  CBL  PTPN11  GATA2  ASXL2  CEBPA  SETD2  MYC  CSF3R  FLT3.ITD  IKZF1  ETV6  EZH2  ASXL1  FLT3.C  TET2  TP53  RUNX1  IDH2  IDH1  NPM1 FLT3  KRAS  NRAS  RUNX1  TP53  WT1   CEBPA  DNMT3A  FLT3  KRAS  NRAS  RUNX1  TP53  WT1   CEBPA  DNMT3A  FLT3  KRAS  NRAS  RUNX1  TP53  WT1   CEBPA  DNMT3A  FLT3  KRAS  NRAS  RUNX1  TP53 PDGFD  PTPRB  CHFR  JAG1  AXIN2  HLF  THEM4  ZNF334  ZNF229  PRKD1  ZNF112  CBR1  SMC1B  DLL3  CDKN2B  RYR1  CIITA  HES1  WIF1  SFRP5  ULBP1  KLF4  YAP1  THRB  ULBP3  DKK1  ULBP2  GAS2L3  PCCA  ALDH2  HOPX  IRF1  IL2RA  MIR150  ZNF254  ZNF43  SPRY1  ZNF256  ZNF44  DNMT3A  VAT1  PDGFRB  LIF  TET1  GPX3  SFRP4  DAXX  ASB2  GSTM1   ZNF254  ZNF43  ZNF256  ZNF44   ULBP3  DKK1  ULBP2   WIF1  SFRP5  ULBP1   CDKN2B   ZNF112 
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